Science Daily: Pharmacology News
APRIL 2, 2024
Australia could soon see megadroughts that last for more than 20 years, according to new modelling. The researchers' bleak findings are before factoring in human impact on the climate since the Industrial Revolution. According to the scientists, the findings paint a worrying picture of future droughts in Australia that are far worse than anything in recent experience.
BioPharma Drive: Drug Pricing
APRIL 2, 2024
Stalking horse bidder Merz Therapeutics could get rights to Acorda’s three marketed drugs if its $185 million proposal holds.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Science Daily: Pharmacology News
APRIL 2, 2024
Researchers have taken a big step towards securing information against hacking. They have succeeded in using quantum encryption to securely transfer information 100 kilometers via fiber optic cable -- roughly equivalent to the distance between Oxford and London.
BioPharma Drive: Drug Pricing
APRIL 2, 2024
An acquisition of Modulus Therapeutics is the latest move by Ginkgo to accumulate technologies that can help other companies develop cellular medicines.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Science Daily: Pharmacology News
APRIL 2, 2024
One of the great mysteries of modern science is dark matter. We know dark matter exists thanks to its effects on other objects in the cosmos, but we have never been able to directly see it. And it s no minor thing currently, scientists think it makes up about 85% of all the mass in the universe.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Broad Institute
APRIL 2, 2024
Scientists link certain gut bacteria to lower heart disease risk By Allessandra DiCorato April 2, 2024 Breadcrumb Home Scientists link certain gut bacteria to lower heart disease risk Study finds several species of cholesterol-metabolizing bacteria in people with lower cholesterol levels. By Allessandra DiCorato April 2, 2024 Credit: Ahmed Mohamed Rod-shaped Oscillibacter sp. bacteria take up fluorescently labeled cholesterol (here shown in green).
BioPharma Drive: Drug Pricing
APRIL 2, 2024
While the company claimed its shot showed signs of working in a Phase 2 trial, the data weren’t strong enough to prove a treatment benefit.
Cytel
APRIL 2, 2024
Data monitoring committees (DMCs) review ongoing clinical trial data to make recommendations regarding trial conduct based on risk-benefit. DMCs are an essential component to ensuring the integrity and safety of clinical trials. New draft guidance published by the U.S. FDA on the use of DMCs in clinical trials provides six major updates to the FDA’s expectations regarding DMC structure and practice.
BioPharma Drive: Drug Pricing
APRIL 2, 2024
A Pfizer drug licensed to a Roivant subsidiary surpassed expectations in a type of uveitis, while a stock purchase plan will see Roivant buy out shares owned by Sumitomo Pharma.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
FDA Law Blog: Biosimilars
APRIL 2, 2024
By Sara W. Koblitz — Every year, federal agencies submit a budget request to Congress to fund various agency initiatives, and every year FDA includes a list of legislative proposals that it would like to see come out of Congress. This year is no different , and in fact some of the requests on this year’s list are repeat offenders from last year’s. And though FDA may not have gotten everything that it wanted last year, reviewing and reflecting on these lists of legislative proposals provides im
BioPharma Drive: Drug Pricing
APRIL 2, 2024
The Dementia Discovery Fund set out to spark research into new approaches for diseases like Alzheimer’s, even as anti-amyloid therapies reach patients.
ASPET
APRIL 2, 2024
Bromine domain protein 2 (BRD2), a member of the Bromodomain and extraterminal domain (BET) protein family, is a crucial epigenetic regulator with significant function in various diseases and cellular processes. The central function of BRD2 is modulating gene transcription by binding to acetylated lysine residues on histones and transcription factors.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Channels
APRIL 2, 2024
This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. For more on acquisition cost reimbursement for pharmacies, see Sections 8.4. and 12.3.4. of our new 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. Click here to see the original post from December 2023.
LifeSciVC
APRIL 2, 2024
By Mike Cloonan, CEO of Sionna Therapeutics, as part of the From The Trenches feature of LifeSciVC An insightful piece on this blog following the JPM healthcare conference noted the “ refreshing burst of enthusiasm ” in the biotech sector. It’s true that venture funds raised significant capital despite numerous challenges over the past two years. And many are looking for the right investments now.
Drug Patent Watch
APRIL 2, 2024
This chart shows the pharmaceutical companies with the most patents in Brazil.
Codon
APRIL 2, 2024
In 1997, as Michael Elowitz was studying for a Ph.D. in physics at Princeton University, he had a remarkable idea: What if it were possible to build a circuit out of DNA, rather than electronics, and use it to “program” a living cell? For the next three years, working with advisor Stanislas Leibler, Elowitz labored over this synthetic gene circuit and achieved precisely that.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drug Patent Watch
APRIL 2, 2024
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.
Antidote
APRIL 2, 2024
Digital advertising, which encompasses social media, online channels, streaming content, and more can be a powerful way to reach patients. One of the biggest avenues of reaching potential clinical trial participants through digital advertising is social media — and from the statistics, it is clear why. Not only does Facebook boast more than 3 billion users every month, but 80% of social media users are searching for health information.
Drug Patent Watch
APRIL 2, 2024
Annual Drug Patent Expirations for EXSERVAN Exservan is a drug marketed by Aquestive and is included in one NDA. It is available from one supplier.
Perficient: Drug Development
APRIL 2, 2024
Introduction: Our organisation celebrated Sankranti, an auspicious occasion that marks the sun’s entry into the northern hemisphere, with a joyful celebration that united staff members in a colourful extravaganza. We made the decision to incorporate teamwork, creativity, and traditions into this year’s celebrations in order to provide everyone an unforgettable time.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drug Patent Watch
APRIL 2, 2024
Annual Drug Patent Expirations for SYMPAZAN Sympazan is a drug marketed by Otter Pharms and is included in one NDA. It is available from one supplier.
Perficient: Drug Development
APRIL 2, 2024
Introduction Custom Hooks are reusable functions that let a React JS developer tailor and adjust a React application’s functionality. React JS version 16.8 includes them. A special JavaScript function with the prefix “use” is referred to as a “ Custom Hooks.” Using a customized Hook, retrieve information from an API. This hook will return an object with the data and an optional error message given a URL.
Drug Patent Watch
APRIL 2, 2024
Annual Drug Patent Expirations for KYNMOBI Kynmobi is a drug marketed by Sumitomo Pharma Am and is included in one NDA. There are fourteen patents protecting this drug.
ASPET
APRIL 2, 2024
Urologic Chronic Pelvic Pain Syndrome (UCPPS) is a painful chronic condition with persistent pain originating from the pelvis that often leads to detrimental lifestyle changes in the affected patients. The syndrome develops in both sexes, with an estimated prevalence of 5.7% to 26.6% worldwide. This narrative review summarizes currently recommended therapies for UCPPS, followed by the latest animal and clinical research advances in the field.
Drug Patent Watch
APRIL 2, 2024
Annual Drug Patent Expirations for ISENTRESS Isentress is a drug marketed by Msd Sub Merck and is included in three NDAs. It is available from nine suppliers.
Expert insights. Personalized for you.
321 
Let's personalize your content